New designer benzodiazepines use in Barcelona

New designer benzodiazepines such as phenazepam, etizolam, diclazepam, clonazolam and flubromazolam have appeared in the recreational drug market due to that they provide an attractive alternative to prescription-only benzodiazepines as they are readily available over the Internet. To describe the p...

Full description

Saved in:
Bibliographic Details
Published inEuropean psychiatry Vol. 41; no. S1; p. S874
Main Authors Pérez González, S., De Dios Felis, M., Monteagudo Gimeno, E., Sanagustín Bosqued, D., Trabsa Biskri, A., Grifell Guàrdia, M., Galindo Guarín, L., Quintana Mathe, P., Torrens Melich, M.
Format Journal Article
LanguageEnglish
Published Elsevier Masson SAS 01.04.2017
Online AccessGet full text

Cover

Loading…
Abstract New designer benzodiazepines such as phenazepam, etizolam, diclazepam, clonazolam and flubromazolam have appeared in the recreational drug market due to that they provide an attractive alternative to prescription-only benzodiazepines as they are readily available over the Internet. To describe the presence of new designer benzodiazepines in samples delivered to energy control since 2010 to 2016 in Barcelona. From 2010 to 2016, 24,551 samples were delivered to energy control. Among this samples 43 (0.175%) were analysed as benzodiazepines. They were analyzed by energy control, a Spanish harm reduction NGO that offers the possibility of analyzing the substances that users report. Analysis was done by gas chromatography-mass spectrometry. From the 43 samples analyzed as benzodiazepines, 1 (2.32%) was delivered in 2010, none in 2011, 2 (4.65%) in 2012, 2 (4.65%) in 2013, 1 (2.32%) in 2014, 15 (34.88%) in 2015 and 21 (48.83%) in 2016. The data shows that new designer benzodiazepines use is increasing in Barcelona, especially in the last two years. Abuse an addiction to these drugs may be a new public health problem in Barcelona. Unknown side effects may appear due to lack of information about pharmacokinetic profile of these drugs.
AbstractList Introduction New designer benzodiazepines such as phenazepam, etizolam, diclazepam, clonazolam and flubromazolam have appeared in the recreational drug market due to that they provide an attractive alternative to prescription-only benzodiazepines as they are readily available over the Internet. Objective To describe the presence of new designer benzodiazepines in samples delivered to energy control since 2010 to 2016 in Barcelona. Methods From 2010 to 2016, 24,551 samples were delivered to energy control. Among this samples 43 (0.175%) were analysed as benzodiazepines. They were analyzed by energy control, a Spanish harm reduction NGO that offers the possibility of analyzing the substances that users report. Analysis was done by gas chromatography-mass spectrometry. Results From the 43 samples analyzed as benzodiazepines, 1 (2.32%) was delivered in 2010, none in 2011, 2 (4.65%) in 2012, 2 (4.65%) in 2013, 1 (2.32%) in 2014, 15 (34.88%) in 2015 and 21 (48.83%) in 2016. Discussion The data shows that new designer benzodiazepines use is increasing in Barcelona, especially in the last two years. Abuse an addiction to these drugs may be a new public health problem in Barcelona. Unknown side effects may appear due to lack of information about pharmacokinetic profile of these drugs. Disclosure of interest The authors have not supplied their declaration of competing interest.
New designer benzodiazepines such as phenazepam, etizolam, diclazepam, clonazolam and flubromazolam have appeared in the recreational drug market due to that they provide an attractive alternative to prescription-only benzodiazepines as they are readily available over the Internet. To describe the presence of new designer benzodiazepines in samples delivered to energy control since 2010 to 2016 in Barcelona. From 2010 to 2016, 24,551 samples were delivered to energy control. Among this samples 43 (0.175%) were analysed as benzodiazepines. They were analyzed by energy control, a Spanish harm reduction NGO that offers the possibility of analyzing the substances that users report. Analysis was done by gas chromatography-mass spectrometry. From the 43 samples analyzed as benzodiazepines, 1 (2.32%) was delivered in 2010, none in 2011, 2 (4.65%) in 2012, 2 (4.65%) in 2013, 1 (2.32%) in 2014, 15 (34.88%) in 2015 and 21 (48.83%) in 2016. The data shows that new designer benzodiazepines use is increasing in Barcelona, especially in the last two years. Abuse an addiction to these drugs may be a new public health problem in Barcelona. Unknown side effects may appear due to lack of information about pharmacokinetic profile of these drugs.
Author De Dios Felis, M.
Grifell Guàrdia, M.
Torrens Melich, M.
Quintana Mathe, P.
Pérez González, S.
Sanagustín Bosqued, D.
Monteagudo Gimeno, E.
Galindo Guarín, L.
Trabsa Biskri, A.
Author_xml – sequence: 1
  givenname: S.
  surname: Pérez González
  fullname: Pérez González, S.
– sequence: 2
  givenname: M.
  surname: De Dios Felis
  fullname: De Dios Felis, M.
– sequence: 3
  givenname: E.
  surname: Monteagudo Gimeno
  fullname: Monteagudo Gimeno, E.
– sequence: 4
  givenname: D.
  surname: Sanagustín Bosqued
  fullname: Sanagustín Bosqued, D.
– sequence: 5
  givenname: A.
  surname: Trabsa Biskri
  fullname: Trabsa Biskri, A.
– sequence: 6
  givenname: M.
  surname: Grifell Guàrdia
  fullname: Grifell Guàrdia, M.
– sequence: 7
  givenname: L.
  surname: Galindo Guarín
  fullname: Galindo Guarín, L.
– sequence: 8
  givenname: P.
  surname: Quintana Mathe
  fullname: Quintana Mathe, P.
– sequence: 9
  givenname: M.
  surname: Torrens Melich
  fullname: Torrens Melich, M.
BookMark eNqFj9FKwzAYhYNMsJs-gtAXaM3fNE1yJTp0CkNv9DqkyV9JmWlJnLI9vR313qtzc87H-ZZkEYaAhFwDLYFCc9OXuI9jOpQVBVFSKEFweUYyEEIWjEu-IBlVVV0oxuQFWabU06lJaZOR4gV_cofJfwSMeYvhODhvjjj6gCnfJ8x9yO9NtLgbgrkk553ZJbz6yxV5f3x4Wz8V29fN8_puW1jgtSw6q9Agc6rtECQ3nDNoRG0AG6W4kEZ0FXABFiRrHKtYqyrXMAUdb52UnK0In7k2DilF7PQY_aeJBw1Un5x1r2dnfXLWFPTJedrdzjuczn17jDpZj8Gi8xHtl3aD_4fwC-1fYzU
CitedBy_id crossref_primary_10_1111_add_15734
ContentType Journal Article
Copyright 2017
Copyright_xml – notice: 2017
DBID AAYXX
CITATION
DOI 10.1016/j.eurpsy.2017.01.1758
DatabaseName CrossRef
DatabaseTitle CrossRef
DatabaseTitleList CrossRef

DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1778-3585
EndPage S874
ExternalDocumentID 10_1016_j_eurpsy_2017_01_1758
S092493381731773X
GroupedDBID ---
--K
--M
.1-
.FO
.~1
09C
09E
0R~
0SF
1B1
1P~
1~.
1~5
29G
4.4
457
4G.
53G
5GY
5VS
7-5
71M
8FI
8FJ
8P~
AABNK
AACTN
AAEDT
AAEDW
AAEED
AAFWJ
AAIKJ
AAKOC
AALRI
AANRG
AAOAW
AAQFI
AAQXK
AASVR
AAXUO
ABBQC
ABBZL
ABFNM
ABIVO
ABJNI
ABMZM
ABUWG
ABXDB
ABYKQ
ACDAQ
ACGFS
ACHQT
ACIUM
ACQPF
ACZWT
ADAZD
ADBBV
ADDNB
ADEZE
ADKIL
ADMUD
ADOVH
ADVJH
AEBAK
AEBPU
AEKER
AENCP
AENEX
AEVXI
AEYHU
AFCTW
AFKRA
AFPKN
AFRHN
AFTJW
AGABE
AGHFR
AGJUD
AGUBO
AGYEJ
AHIPN
AHRGI
AITUG
AJBFU
AJOXV
AJPFC
AJRQY
AJUYK
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
ANZVX
AQJOH
ASPBG
AVWKF
AZFZN
AZQEC
BENPR
BLXMC
BLZWO
CCPQU
CCUQV
CFBFF
CGQII
CJCSC
CS3
DOHLZ
DU5
DWQXO
EBS
EFLBG
EGQIC
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYUFA
G-Q
GBLVA
GNUQQ
GROUPED_DOAJ
HVGLF
HZ~
IHE
IKXGN
IOO
IPYYG
J1W
LCYCR
LN9
LW7
M2M
M41
MO0
N9A
NCXOZ
NZEOI
O-L
O9-
OAUVE
OH0
OK1
OU-
OZT
P-8
P-9
P2P
PC.
PIMPY
PSYQQ
Q38
R2-
RCA
RIG
ROL
RPM
RPZ
SCC
SDF
SDG
SDP
SES
SEW
SSZ
T5K
UHS
UKHRP
UV1
WFFJZ
Z5R
~G-
AAYXX
ABVZP
ABXAU
ADVLN
AKRWK
ALIPV
CCQAD
CITATION
CTKSN
ID FETCH-LOGICAL-c1548-fc9eae3d9bfe185a5531674a1e699578a7f21571c1836d323b92d6391f5bd8853
IEDL.DBID .~1
ISSN 0924-9338
IngestDate Thu Sep 26 16:14:43 EDT 2024
Fri Feb 23 02:24:07 EST 2024
IsPeerReviewed true
IsScholarly true
Issue S1
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c1548-fc9eae3d9bfe185a5531674a1e699578a7f21571c1836d323b92d6391f5bd8853
ParticipantIDs crossref_primary_10_1016_j_eurpsy_2017_01_1758
elsevier_sciencedirect_doi_10_1016_j_eurpsy_2017_01_1758
PublicationCentury 2000
PublicationDate April 2017
2017-04-00
PublicationDateYYYYMMDD 2017-04-01
PublicationDate_xml – month: 04
  year: 2017
  text: April 2017
PublicationDecade 2010
PublicationTitle European psychiatry
PublicationYear 2017
Publisher Elsevier Masson SAS
Publisher_xml – name: Elsevier Masson SAS
SSID ssj0017006
Score 2.1982977
Snippet New designer benzodiazepines such as phenazepam, etizolam, diclazepam, clonazolam and flubromazolam have appeared in the recreational drug market due to that...
Introduction New designer benzodiazepines such as phenazepam, etizolam, diclazepam, clonazolam and flubromazolam have appeared in the recreational drug market...
SourceID crossref
elsevier
SourceType Aggregation Database
Publisher
StartPage S874
Title New designer benzodiazepines use in Barcelona
URI https://dx.doi.org/10.1016/j.eurpsy.2017.01.1758
Volume 41
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV07a8MwEBYhQ-lS-qTpI2joqjh-yJbGNjSUQrq0gWxCL0NCcUweQzP0t_fOjz6gdOhocwL5TrrvzvruRMiNkxmArtBMcGNYEoaSySjlTDtIgYaJttLiD_3JU_owTR5nfNYho7YWBmmVje-vfXrlrZs3QaPNoJzPg-chpg4xdpgDDMziGVawA_zBmh68f9I8sP1cdV4Jwgylv6p4ggX2VizXb0jwyrB5J0Cp-B2fvmHO-JAcNMEiva3nc0Q6vjgme5PmOPyEMHBR1FUcDL-ixhe7JZh750vkstPt2tN5Qe-wmvEVAu5TMh3fv4weWHP_AbOYSLDcSq997KTJPcCq5hzL1hMd-lRK2Gk6ywGws9DCtkxdHMVGRg4ijjDnxgnA4TPSLZaFPyc0AxlrjTEpt4mw2hjBpRF5pG3s08z0yKD9alXWbS5Uy_9aqFpNCtWkhqFCNfWIaHWjfthLgSv-e-jF_4dekn18rJkzV6S7WW39NQQFG9OvrN6vUuoPUVm1Ew
link.rule.ids 315,783,787,867,4509,27936,27937,45597
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV07T8MwELZKkYAF8RTlmYHVTdPEiT1CRVWg7UIrdbNsx5FaoTTqY6ADv527PHhIiIE1OUvJ2b7vLv7uCyG3sYgAdLminGlNA88TVLRDRlUMJVArUEYY_KA_GIa9cfA0YZMa6VS9MEirLGN_EdPzaF1ecUtvutl06r60sHTwUWEOMDDyJ1tkO8D8GBZ18_2T54H6c_mBJVhTNP9q43FnKK6YLd-Q4RWheidgKf8doL6BTveA7JfZonNXPNAhqdn0iOwMyvPwY0IhRjlxTsKwC0fbdDOH-d7YDMnsznppnWnq3GM74ytk3Cdk3H0YdXq0_AECNVhJ0MQIq6wfC51YwFXFGPatB8qzoRCw1VSUAGJHnoF9GcZ-29eiHUPK4SVMxxyA-JTU03lqz4gTgY0xWuuQmYAbpTVnQvOkrYxvw0g3SLN6a5kVOheyIoDNZOEmiW6SLU-imxqEV76RPyZMQiz-e-j5_4fekN3eaNCX_cfh8wXZw1sFjeaS1FeLtb2CDGGlr_MV8AFIn7dF
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=New+designer+benzodiazepines+use+in+Barcelona&rft.jtitle=European+psychiatry&rft.au=P%C3%A9rez+Gonz%C3%A1lez%2C+S.&rft.au=De+Dios+Felis%2C+M.&rft.au=Monteagudo+Gimeno%2C+E.&rft.au=Sanagust%C3%ADn+Bosqued%2C+D.&rft.date=2017-04-01&rft.issn=0924-9338&rft.eissn=1778-3585&rft.volume=41&rft.issue=S1&rft.spage=S874&rft.epage=S874&rft_id=info:doi/10.1016%2Fj.eurpsy.2017.01.1758&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_eurpsy_2017_01_1758
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0924-9338&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0924-9338&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0924-9338&client=summon